GW Pharma expects fiscal 2020 sales to reach $526 million
United Kingdom-based GW Pharmaceuticals expects to report annual sales of approximately $526 million for the year ended Dec. 31, 2020,…
United Kingdom-based GW Pharmaceuticals expects to report annual sales of approximately $526 million for the year ended Dec. 31, 2020,…
Sales of medical marijuana in Denmark posted healthy gains in the third quarter of 2020, coinciding with the launch of…
Canopy Growth Corporation acquired a patented cannabis extraction technique that GW Pharmaceuticals allegedly infringed. So, two giant players in Canada’s…
Canadian cannabis producer Canopy Growth Corp. is suing Britain’s GW Pharmaceuticals in U.S. federal court, alleging that GW is knowingly…
United Kingdom-based GW Pharmaceuticals posted higher revenue in the quarter ended Sept. 30, largely driven by U.S. sales of its…
United Kingdom-based GW Pharmaceuticals posted higher revenue in the quarter ended Sept. 30, largely driven by sales of its cannabidiol…
GW Pharmaceuticals’ plant-derived CBD drug Epidyolex received approval from Australia’s Therapeutic Goods Administration (TGA) to be used in treating seizures…
The Curious Case Of GW Pharmaceuticals When a company uses marijuana prohibition and the Drug War to lobby for state violence against…
United Kingdom-based GW Pharmaceuticals posted marginal revenue growth in the second quarter over the previous quarter, citing challenges stemming from…
United Kingdom-based GW Pharmaceuticals posted marginal revenue growth over the previous quarter, citing challenges stemming from the COVID-19 pandemic. GW…